Trial reportFrontiers in veterinary science2026
Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot study.
Trial report in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Treatments for canine osteoarthritis, a degenerative joint disease associated with impaired mobility and pain, which is common in older dogs, are limited. The objective of this clinical study was to investigate the efficacy and safety of piclidenoson (an agonist at the A3 adenosine receptor) for canine osteoarthritis. Methods: Client-owned dogs with spontaneously developed osteoarthritis and a score ≥11 at baseline on the Liverpool Osteoarthritis in Dogs (LOAD) were randomized to PO piclidenoson at 100 or 500 μg/kg bid and followed for 90 days. The primary efficacy endpoint was change in LOAD score from baseline to Day 90. Results: The safety population included 21 dogs (100 μg/kg bid, Clinical significance: Piclidenoson was well tolerated, and the findings suggest potential efficacy, thus supporting its further evaluation as a treatment for canine osteoarthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.